Axsome Therapeutics

Lundbeck

Follow

Today, millions of people all over the world live with brain diseases. Every day, at Lundbeck we strive to further understand these diseases, develop the best therapies to treat them and make a difference to people living with them. We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization. Our purpose is clear: We are committed to advancing brain health and transforming lives Driven by research… For more than 70 years, we’ve been pushing the boundaries of neuroscience. By combining the logic of science with our passion for making a difference to patients, we’ve pioneered some of the most important and commonly used therapies within antipsychotics and antidepressants. We work closely with patients, healthcare professionals and the neuroscience community to uncover causes and to find new treatments that can bring back quality of life to people living with brain diseases. …raising our voice… When every other organ in our body gets sick, we find compassion and care. When our brain suffers, the world typically turns away. As a global specialist, we owe it to those who live with brain diseases to fight stigma and promote better treatment. That’s why we work to improve understanding and parity of care across communities and societies – so we can empower people and rebuild hope. …giving profit a purpose… The Lundbeck Foundation is the majority owner of Lundbeck. Foundation ownership allows us to stay focused on our areas of specialization. It also means that we are in a position to give back. With donations of approximately DKK 500 million a year to biomedical research, the foundation supports the progress of health science. …and working with one aim. Today, we’re over 5,000 people in +20 countries. We build on our Danish heritage, fostering a culture of collaboration and responsibility. Whether we work in labs or in the field, we all have the same aim: to develop innovative treatments that improve the lives of people living with brain diseases.

Neurocrine Biosciences

Follow

Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)

Otsuka

Follow

Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. are the US-based indirect subsidiaries of the global healthcare company Otsuka Pharmaceutical Co. Ltd with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka’s US companies share a deep commitment to the development and commercialization of innovative products in the spaces of neuroscience, nephrology, and immunology. Driven by our purpose to defy limitation, so that others can too, we have an unwavering belief in doing more and going above and beyond — under any circumstances- so that patients can push past the limitations of their disease and achieve more than they thought was possible every day. OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed over 34,000 people worldwide and had consolidated sales of approximately USD 14.2 billion in 2023. We invite you to explore our open positions for an opportunity to join our many colleagues in the U.S. whose passion for our mission and pride in our company have earned us certification as a Great Place to Work by the Great Place to Work Institute.